PainReformPRFX
PRFX
About: PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
Employees: 7
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 4 [Q2] → 4 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
7.21% less ownership
Funds ownership: 12.19% [Q2] → 4.98% (-7.21%) [Q3]
76% less capital invested
Capital invested by funds: $145K [Q2] → $35.2K (-$110K) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for PRFX.
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial
TEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the receipt of partial topline data from its contract research organization (CRO), Lotus Clinical Research ("Lotus"), for the Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy.
Neutral
GlobeNewsWire
1 month ago
PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has received a notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer satisfied the minimum $2.5 million stockholders' equity requirement for continued listing on Nasdaq set forth in Nasdaq Listing Rule 5550(b)(1) (the “Minimum Equity Rule”) or, alternatively, the requirement that the Company either maintain a market value of listed securities of at least $35 million or generate net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last three most recently completed fiscal years.
Neutral
GlobeNewsWire
3 months ago
PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110
Positive Compatibility Results Reinforce Safety and Efficacy of PRF-110 in Post-Surgical Pain Management Positive Compatibility Results Reinforce Safety and Efficacy of PRF-110 in Post-Surgical Pain Management
Neutral
GlobeNewsWire
3 months ago
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds
TEL AVIV, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 989,300 ordinary shares of the Company originally issued in December 2023 and April 2024, having an exercise price of $4.80 per share, at a reduced exercise price of $1.60 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form F-3 (File No. 333-276485) and Form F-1 (File No. 333-277594). The offering is expected to close on or about September 11, 2024, subject to satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
4 months ago
PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study
TEL AVIV, Israel, Aug. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced encouraging early safety results from its ongoing Phase 3 bunionectomy study of PRF-110, the Company's proprietary post-surgical pain formulation.
Neutral
GlobeNewsWire
4 months ago
PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses
TEL AVIV, Israel, Aug. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced compelling safety data for its lead product candidate, PRF-110. This data, derived from pharmacokinetic (PK) studies in both herniorrhaphy and bunionectomy clinical trials, highlights PRF-110's promising safety profile, with maximum blood levels (Cmax) recorded at approximately 10% of the FDA-established safety threshold.
Neutral
GlobeNewsWire
4 months ago
PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature
New process expected to significantly bolster future commercialization efforts New process expected to significantly bolster future commercialization efforts
Neutral
GlobeNewsWire
6 months ago
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the “Letter”), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
Neutral
GlobeNewsWire
7 months ago
PainReform Provides Business Update for the First Quarter of 2024
Reaches 50% e nrollment in the s econd p art of its Phase 3 c linical t rial of PRF-110 in b unionectomy
Neutral
GlobeNewsWire
7 months ago
PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com
TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, participated in an interview with Proactiveinvestors.com.
Charts implemented using Lightweight Charts™